Skip to content

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06894004
Enrollment
100
Registered
2025-03-25
Start date
2025-02-24
Completion date
2030-11-30
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia and Hyperlipidemia

Keywords

LDL-cholesterol, cholesterol, ketogenic diet, lipoprotein kinetics

Brief summary

Very-low carbohydrate ketogenic diets can dramatically increase blood cholesterol levels, particularly in normal-weight people, for reasons that are not well understood. This study will enroll normal-weight adults, will identify "responders" who develop high cholesterol on a ketogenic diet, and will measure rates of production and removal of certain types of cholesterol-carrying particles called lipoproteins in responders. The results will clarify the mechanism by which a ketogenic diet can cause high cholesterol in certain susceptible people.

Detailed description

This study will evaluate the mechanism of ketogenic diet-induced hypercholesterolemia in susceptible normal-weight adults. The first stage of screening will identify eligible young adults who are normal-weight and at low cardiovascular risk. The second stage of screening will identify "responders" who demonstrate susceptibility to ketogenic diet-induced hypercholesterolemia by displaying an increase in LDL-cholesterol concentration after a 3-week screening ketogenic diet. Responders will be eligible to complete a randomized crossover clinical study at Washington University School of Medicine in St. Louis, MO. The randomized crossover study will involve isotope tracer studies of lipoprotein and cholesterol kinetics after two separate 4-week dietary interventions \[ketogenic diet and control diet\], conducted in random order with a 4-week washout period between interventions. All food will be provided to the participants as packed-out meals. Certain outcomes will use data from the screening process, comparing screen successes and screen failures to evaluate factors that could influence susceptibility to ketogenic diet-induced hypercholesterolemia.

Interventions

BEHAVIORALKetogenic Diet

Participants will consume an isocaloric ketogenic diet for 4 weeks with all food provided as packed-out meals.

BEHAVIORALControl Diet

Participants will consume an isocaloric control diet for 4 weeks with all food provided as packed-out meals.

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

1. age ≥ 18 and \< 40 years 2. BMI ≥ 18.5 and \< 25.0 kg/m2 3. baseline serum LDL-c \< 150 mg/dL (\< 3.9 mmol/L) 4. baseline serum TG \< 100 mg/dL (\< 1.1 mmol/L) 5. HbA1c ≤ 5.6%.

Exclusion criteria

1. personal or family history of familial hypercholesterolemia 2. current use of lipid-lowering drugs 3. currently on a ketogenic diet and unwilling to change diet 4. current tobacco use 5. hypertension 6. prediabetes or diabetes 7. elevated Lp(a) \> 6.5% of ApoB-containing lipoproteins at baseline 8. oral contraceptive use 9. contraindication to heparin 10. known atherosclerotic cardiovascular disease 11. unwilling to abstain from alcohol

Design outcomes

Primary

MeasureTime frameDescription
VLDL-ApoB100 production rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and VLDL-ApoB100 leucine isotopic enrichment and compartmental modeling

Secondary

MeasureTime frameDescription
VLDL-ApoB100 fractional catabolic rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and VLDL-ApoB100 leucine isotopic enrichment and compartmental modeling
IDL-ApoB100 production rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and IDL-ApoB100 leucine isotopic enrichment and compartmental modeling
IDL-ApoB100 fractional catabolic rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and IDL-ApoB100 leucine isotopic enrichment and compartmental modeling
LDL-ApoB100 production rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and LDL-ApoB100 leucine isotopic enrichment and compartmental modeling
LDL-ApoB100 fractional catabolic rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and LDL-ApoB100 leucine isotopic enrichment and compartmental modeling
VLDL-triglyceride production rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and VLDL glycerol isotopic enrichment and compartmental modeling
VLDL-triglyceride fractional catabolic rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and VLDL glycerol isotopic enrichment and compartmental modeling
Plasma lipoprotein lipase activityImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by assaying lipoprotein lipase activity in post-heparin plasma
Plasma lipoprotein profileAt baseline, immediately after the screening ketogenic diet, immediately after the 4-week ketogenic diet intervention period, and immediately after the 4-week control diet intervention period.Determined by standard clinical chemistry methods and by advanced lipoprotein profiling
Whole-body lipolytic rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma palmitate isotopic enrichment
Relative contribution of systemic fatty acids to VLDL-triglycerideImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using plasma and VLDL-triglyceride palmitate isotopic enrichment and compartmental modeling
Cholesterol synthetic rateImmediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.Determined by using mass isotopomer distribution analysis of deuterium enrichment in plasma cholesterol after labeling the total body water pool with deuterium oxide
Fat massImmediately after the screening ketogenic dietDetermined by using dual-energy X-ray absorptiometry
Fat-free massImmediately after the screening ketogenic dietDetermined by using dual-energy X-ray absorptiometry
Insulin sensitivityImmediately after the screening ketogenic dietDetermined by measuring fasting plasma glucose, insulin, and C-peptide
Thyroid functionImmediately after the screening ketogenic dietDetermined by measuring TSH, free T4, and free T3
AdipokinesImmediately after the screening ketogenic dietDetermined by measuring plasma leptin and adiponectin
Cholesterol absorption markersImmediately after the screening ketogenic dietDetermined by measuring serum campesterol, sitosterol, and cholestanol

Countries

United States

Contacts

CONTACTFrannie Wilkinson, M.A.
francesw@wustl.edu(314) 362-0590
CONTACTMax C Petersen, M.D., Ph.D.
max.p@wustl.edu314-362-8352
PRINCIPAL_INVESTIGATORMax C Petersen, M.D., Ph.D.

Washington University School of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026